Dipropylamino-acetamid | 7409-49-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Dipropylamino-acetamid
• 英文别名: Acetamide, 2-(dipropylamino)-；2-(dipropylamino)acetamide
• CAS: 7409-49-6
• 化学式: C₈H₁₈N₂O
• mdl: MFCD11938911
• 分子量: 158.244
• InChiKey: XZQWFOMYAIGUFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Amine compounds and use thereof
  申请人：Yamazaki Toru

  公开号：US20050165063A1

  公开（公告）日：2005-07-28

  It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1): In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(═O) or NR11; and D is a group represented by the following general formula (4) or (6). In the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7). z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.

  本发明旨在提供新型胺化合物，其对感染HIV病毒、风湿病和癌症转移等疾病具有疗效。即以下通式（1）所代表的胺化合物：在典型情况下，A1和A2分别代表可选择取代的单环或多环芳香杂环；W代表环状C3-10烷基，可选择取代的单环或多环芳香杂环，单环或多环芳香环或部分饱和多环芳香环；X代表O，CH2，C（═O）或NR11；D是以下通式（4）或（6）所代表的基团。在公式（6）中，Q代表单键，S，O或NR12；Y代表以下通式（7）所代表的基团。z代表可选择取代的单环或多环芳香环。在公式（6）中，B代表NR25R26。在上述公式中，R1至R26每个代表氢，烷基，烯基或炔基。
• NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS
  申请人：Lopez Roman

  公开号：US20130023521A1

  公开（公告）日：2013-01-24

  The present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use.

  本发明涉及新型选择性泛素特异性蛋白酶抑制剂的发现，它们的制备过程及其治疗用途。
• ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS
  申请人：Turnbull Philip Stewart

  公开号：US20090163588A1

  公开（公告）日：2009-06-25

  This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.

  本发明涉及非类固醇化合物，它们是雄激素、糖皮质激素、矿物质皮质激素和孕激素受体的调节剂，以及制备和使用这些化合物的方法。
• AMINE COMPOUNDS AND USE THEREOF
  申请人：Kureha Chemical Industry Co., Ltd.

  公开号：EP1550657A1

  公开（公告）日：2005-07-06

  It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1): In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(=O) or NR11; and D is a group represented by the following general formula (4) or (6).         -Q-Y-B     (6) In the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7). z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.

  本发明旨在提供新型胺化合物，这些化合物对艾滋病病毒感染、风湿病和癌症转移等疾病具有疗效。即由以下通式（1）代表的胺化合物： 在典型情况下，A1 和 A2 分别代表任选取代的单环或多环芳香杂环；W 代表环 C3-10 烯、任选取代的单环或多环芳香杂环、单环或多环芳香环或部分饱和的多环芳香环；X 代表 O、CH2、C(=O) 或 NR11；以及 D 是由以下通式（4）或（6）代表的基团。 -Q-Y-B (6) 在式 (6) 中，Q 代表单键、S、O 或 NR12；Y 是由下式通式 (7) 所代表的基团。 z 代表任选取代的单环或多环芳香环。在式 (6) 中，B 代表 NR25R26。在上式中，R1 至 R26 各自代表氢、烷基、烯基或炔基。
• Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7
  申请人：Hybrigenics S.A.

  公开号：EP2523938B1

  公开（公告）日：2014-09-03